Prevalence and risk factors associated with resistance-associated mutations to etravirine in a cohort of perinatally HIV-infected children

Vista sencilla de ítem
dc.contributor.authorContreras, German A.
dc.contributor.authorBell, Cynthia S.
dc.contributor.authorDel Bianco, Gabriela P.
dc.contributor.authorPérez, Norma
dc.contributor.authorKleinosky, Matthew T.
dc.contributor.authorMurphy, James R.
dc.contributor.authorHeresi, Gloria P.
dc.date.accessioned2020-07-27T20:43:33Z
dc.date.available2020-07-27T20:43:33Z
dc.date.issued2013
dc.description.abstractenglishEtravirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with reduced cross-resistance to first-generation NNRTIs. Because many perinatally HIV-infected patients have been treated with first-generation NNRTIs, they may have acquired resistance-associated mutations to etravirine (RAMe). We determined for the interval 1998–2009 the prevalence and factors associated with the presence of RAMe. Twenty-three of 66 (34.8%) children had RAMe; the most common were 181C (19.6%), 190A (7.5%), 98G (6%), 106I (4.5%), 179D (4.5%), 100I (3%), 181I (1.5%), 138A (1.5%) and 179T (1.5%). Eleven children with RAMe (17%) had a mutation score between 2.5 and 3.5 and 1 (1.5%) a score ≥4, indicating an intermediate and reduced response to etravirine. For each 1% increase in CD4% there is a 7% decrease in the odds of RAMe (OR 0.93; 95% CI 0.88–0.97; P < 0.01). History of nevirapine use (OR 8.95; 95% CI 2.31–34.73; P < 0.01) and Hispanic ethnicity (OR 4.76; 95% CI 1.03–21.87; P = 0.04) are significantly associated with risk of RAMe. RAMe are present and common among antiretroviral-experienced perinatally HIV-infected children without previous exposure to etravirine. This could limit the efficacy of etravirine-based regimens. In addition, our results underscore the importance of taking previous history of nevirapine into account for combined antiretroviral therapy regimens that contain etravirine.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1093/jac/dkt198
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1460-2091
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlhttps://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/3584
dc.language.isoeng
dc.publisherOxford University Pressspa
dc.publisher.journalJournal of Antimicrobial Chemotherapyspa
dc.relation.ispartofseriesJournal of Antimicrobial Chemotherapy, 1460-2091, Vol. 68, No. 10, 2013 p. 2344-2348spa
dc.relation.urihttps://academic.oup.com/jac/article/68/10/2344/716956
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2013-10
dc.rights.localAcceso abiertospa
dc.subject.decsAntiviralesspa
dc.subject.decsVIHspa
dc.subject.decsNiñospa
dc.subject.keywordsTherapy adherencespa
dc.subject.keywordsCumulative HIV RNAspa
dc.subject.keywordsHispanicsspa
dc.titlePrevalence and risk factors associated with resistance-associated mutations to etravirine in a cohort of perinatally HIV-infected childrenspa
dc.title.translatedPrevalence and risk factors associated with resistance-associated mutations to etravirine in a cohort of perinatally HIV-infected childrenspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Contreras_German_A_2013.pdf
Tamaño:
171.79 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos